Sodium Hyaluronate Eye Drops Companies

Santen acquires Inotek Pharmaceuticals: This strengthens Santen's ophthalmic portfolio and gives them access to Inotek's hyaluronic acid-based dry eye treatment pipeline. (December 2023)

Bausch + Lomb partners with Alcon for distribution of its new preservative-free HA eye drops in Europe: This expands B+L's reach and leverages Alcon's extensive European distribution network. (November 2023)

Thea Laboratories partners with Bausch + Lomb for development and commercialization of a novel HA-based eye drop in Asia: This collaboration combines Thea's expertise in HA and B+L's commercial reach in Asia. (October 2023)

Allergan receives FDA approval for their new long-lasting HA eye drop: This innovative product offers extended relief for dry eye sufferers, potentially disrupting the market. (December 2023)

Alcon initiates Phase 3 trial for its next-generation HA eye drop with improved lubrication: This advancement could offer sustained comfort and potentially attract new market segments. (November 2023)

Santen completes Phase 2 trial for a new biocompatible HA eye drop, showing positive safety and efficacy results: This could lead to accelerated development and market entry. (October 2023)

List of Sodium Hyaluronate Eye Drops Key Companies in the Market

• URSAPHARM Arzneimittel GmbH


• Santen


• Bayer Inc.


• Bausch and Lomb


• Johnson and Johnson


• The United Laboratories


• Alcon


• Novax Pharma


• Rohto


• Thea Pharmaceuticals


• Scope Ophthalmics Ltd


• Prestige Consumer Healthcare


• Medicom Healthcare Ltd


• Altacor


• Optrex